Colorectal cancer diagnoses in people under 50 now account for nearly half of all new cases, prompting specialized treatment programs that use precision medicine and liquid biopsy technology to customize care based on individual tumor genetics.
Three interconnected life sciences infrastructure markets are experiencing significant growth driven by precision medicine adoption, increasing clinical trial activity, and advances in genomic diagnostics through 2035.
The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
The global genomics in cancer care market is projected to grow from $24.39 billion in 2025 to $108.69 billion by 2035, driven by rising cancer incidence, personalized medicine adoption, and next-generation sequencing advances.
